title: Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done?
authors.affiliation: Department of Renal Medicine, King's College Hospital, London, UK. iainc.macdougall@virgin.net
authors.forename: Iain C
authors.initials: IC
authors.lastname: Macdougall
authors.forename: Alison
authors.initials: A
authors.lastname: Roche
authors.forename: Jerome
authors.initials: J
authors.lastname: Rossert
authors.forename: Nicole
authors.initials: N
authors.lastname: Casadevall
authors.forename: Patrick
authors.initials: P
authors.lastname: Francois
authors.forename: D Michael
authors.initials: DM
authors.lastname: Kemeny
mesh_terms: D000368:Aged; D000906:Antibodies / Q000032:analysis; D000911:Antibodies, Monoclonal; D000068817:Epoetin Alfa; D017707:Erythrocyte Transfusion; D004921:Erythropoietin / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006397:Hematinics / Q000009:adverse effects*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*; D017701:Reticulocyte Count; D019233:Retreatment
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068817:Epoetin Alfa